Condition: Cognitive Decline, Mild · Alzheimer Disease · Sponsor: Helse Stavanger HF
The goal of this placebo-controlled double-blind Phase 2 clinical trial is to test in people with early Alzheimer's Disease. The main questions it aims to answer are: * Does treatment with fasudil, a ROCK-inhibitor, lead to significant improvement in working memory (based on computer-based working memory composite scores) compared to placebo in individuals with early Alzheimer's disease (AD) over 12 months? * What is the effect of fasudil treatment for 12 months on other cognitive functions, brain metabolism measured by Fluorodeoxyglucose Positron Emission Tomography (FDG-PET), and other relevant clinical functions and biomarkers in individuals with early Alzheimer's disease (AD)? * Treatment will be escalated to a maintenance dose of 120 mg total daily dose for up to 50 weeks, with regular clinic visits for efficacy and safety evaluations. * Assessments will include cognitive tests, FDG-PET scans, and biomarker analyses, with follow-up by the Data and Safety Monitoring Board for ongoing safety review. The study will compare participants receiving fasudil with those receiving placebo to see if fasudil treatment leads to improvements in cognitive functions, brain metabolism measured by FDG-PET.
This description comes directly from the study's public registry record.
Dag Aarsland, PhD · +4797575804 · daarsland@gmail.com
Nicolas Castellanos Perilla, MD · +4741279857 · nicolascastellanos1107@gmail.com
Always discuss trial participation with your own doctor first.
| University Hospital of North Norway | Tromsø, Nordland, Norway | Not Yet Recruiting |
| Akershus Hospital: | Oslo, Oslo, Norway | Not Yet Recruiting |
| Haugesund Hospital | Haugesund, Rogaland, Norway | Not Yet Recruiting |
| Stavanger University Hospital | Stavanger, Rogaland, Norway | Recruiting |
| St. Olavs Hospital: | Trondheim, Trøndelag, Norway | Not Yet Recruiting |
| Haraldsplass Deaconess Hospital | Bergen, Vestland, Norway | Enrolling By Invitation |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06362707